Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Total 13F shares
-
54,381,899
-
Share change
-
+127,342
-
Total reported value
-
$2,468,918,179
-
Put/Call ratio
-
105%
-
Price per share
-
$45.39
-
Number of holders
-
395
-
Value change
-
-$2,321,638
-
Number of buys
-
181
-
Number of sells
-
143
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q3 2023
As of 30 Sep 2023,
CRISPR Therapeutics AG - Common Stock (CRSP) was held by
395 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
54,381,899 shares.
The largest 10 holders included
ARK Investment Management LLC, Capital International Investors, T. Rowe Price Investment Management, Inc., Sumitomo Mitsui Trust Holdings, Inc., Nikko Asset Management Americas, Inc., BlackRock Inc., FMR LLC, STATE STREET CORP, NEA Management Company, LLC, and VANGUARD GROUP INC.
This page lists
400
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.